Search Results
Your search for can matches 13815 pages
Showing 2601 - 2650CLN-081 Shows Selective Activity in NSCLC With EGFR Exon 20 Insertions
CLN-081, a novel agent targeted to non–small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations—ie, the addition of nucleotide base pairs in exon 20 of the EGFR gene, a known oncogenic driver event—holds promise, according to the results of...
EAU22: Trial Shows New Imaging Technology May Be Less Accurate Than MRI in Detecting Prostate Cancer
A team of researchers in Australia and New Zealand reported that magnetic resonance imaging (MRI) scans may be able to detect prostate cancer more accurately than the newer, prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scanning technique. The...
EAU22: ctDNA May Help to Predict Response to Atezolizumab in Patients With Bladder Cancer
Researchers who treated a group of patients with bladder cancer with the immunotherapy atezolizumab after they had undergone surgery have found that patients whose blood contained circulating tumor DNA (ctDNA) responded very well to the treatment. The study was presented at the European Association ...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
ASCO’s CancerLinQ and HealthVerity Collaborate to Accelerate Cancer Research
On June 8, 2022, CancerLinQLLC, a wholly owned nonprofit subsidiary of ASCO, and HealthVerity, Inc., announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration...
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
Rapid developments over the past decade in the treatment of patients with advanced HER2-positive breast cancer may lead to better outcomes and improved quality of life for patients with brain metastases, according to findings incorporated into a new ASCO guideline update.1 “The difference this...
CAR T-Cell Therapy Gave Me Back a High-Quality Life
A radiologist by training, I knew the minute I saw the results from my chest x-ray that I had multiple myeloma. In 2015, I was semiretired and had just taken up the game of golf. After making a big swing at the ball, I instantly felt pain in my ribs and thought I had either pulled an intercostal...
Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Expert Point of View: Marianne E. Pavel, MD
Based on the final results of ECOG-ACRIN E2211, invited discussant Marianne E. Pavel, MD, of Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, concluded: “Capecitabine/temozolomide is a preferred regimen…, but temozolomide can still be an option in patients who do not tolerate...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
Expert Point of View: Ben Ho Park, MD, PhD
The invited discussant of the DYNAMIC study was Ben Ho Park, MD, PhD, who said the study “has really moved the needle for circulating tumor DNA [ctDNA] analysis and guiding therapy.” Dr. Park is Director of the Vanderbilt-Ingram Cancer Center, Nashville. Speaking more broadly about the use of...
FDA Launches Campaign Aimed at Preventing E-Cigarette Use Among American Indian/Alaska Native Youth
The U.S. Food and Drug Administration (FDA) recently announced the launch of the “Next Legends” Youth E-cigarette Prevention Campaign as part of the agency’s ongoing efforts to protect youth from the dangers of tobacco use. The campaign will educate American Indian/Alaska Native (AI/AN) youth, ages ...
Circulating Tumor DNA–Guided Approach to Treating Stage II Colon Cancer
The use of postoperative circulating tumor DNA (ctDNA) in stage II colon cancer spared many patients the need for adjuvant chemotherapy without compromising recurrence-free survival, according to the phase II DYNAMIC study.1 “The strategy of using ctDNA results to inform treatment almost halved...
Thomas Stricker, MD, Joins OneOncology as Medical Director for Precision Medicine
OneOncology, headquartered in Nashville, recently appointed Thomas Stricker, MD, as Medical Director for Precision Medicine. Dr. Stricker will work with partner practices to create workflows that reduce physicians’ burden of genomic test ordering and interpretation, allowing more time for...
Death and Clinical Trials in the Plague Years
“Everybody knows that pestilences have a way of recurring in the world; yet somehow, we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise.” —Albert Camus, The...
Expert Point of View: Amir Fathi, MD
Amir Fathi, MD, Associate Professor of Medicine, Harvard Medical School, and Program Director, Center for Leukemia at Massachusetts General Hospital, called the phase III data on quizartinib “compelling” and noted some potential advantages over the first-generation FLT3 inhibitor midostaurin. “The ...
Expert Point of View: Christina Wu, MD
Christina Wu, MD, a gastrointestinal oncologist at the Mayo Clinic in Arizona, emphasized the importance of the IMPROVE study in a Highlights of the Day Session at the 2022 ASCO Annual Meeting. She said the results are not only clinically relevant but practice-changing, and they are in line with...
Intermittent FOLFIRI Plus Panitumumab Proves More Effective, Less Toxic Than Continuous Treatment in Metastatic Colorectal Cancer
In patients with RAS/BRAF wild-type metastatic colorectal cancer, FOLFIRI (fluorouracil, leucovorin, irinotecan) plus panitumumab can be given intermittently rather than continuously, without compromising outcomes, according to the results of the IMPROVE study presented at the 2022 ASCO Annual...
Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
New Study: Patients Report Increased Likelihood to Enroll in Decentralized Clinical Trials
A new article published by Adams et al in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 patients with cancer and survivors, more than 80% said they would be willing to use remote...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Study Examines High Early Death Rates, Treatment Resistance, and Short Survival Among Black AYA Patients With AML
New research published by Larkin et al in the journal Blood Advances has found that Black adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) were five times more likely than comparable White patients to die within 30 days of beginning treatment—and were twice as likely to...
Real-World Treatment Outcomes With Transplantation and Maintenance Rituximab in Previously Untreated Patients With Mantle Cell Lymphoma
In a U.S. “real-world” retrospective cohort study of patients receiving first-line treatment for mantle cell lymphoma reported in the Journal of Clinical Oncology, Peter Martin, MD, and colleagues found that autologous stem cell transplantation (ASCT) did not significantly improve the time to next...
Dual-Targeted Therapy Improves Outcomes vs Chemotherapy for Some Pediatric Patients With Low-Grade Glioma
The all-oral combination of dabrafenib plus trametinib—two targeted therapies—significantly improved the overall response rate vs standard-of-care chemotherapy with carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas. The clinical benefit rate...
EAU22: New Research Supports Risk-Based Prostate Cancer Screening
Data from the world’s largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening program for the disease, said researchers. In 2009, the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that screening can reduce...
EAU22: Study Finds Gut Microbes Differ in Patients With Prostate Cancer vs Those With Benign Biopsy Results
Researchers have found a significant difference in the gut microbiota of patients with prostate cancer compared with those who have benign biopsies. Although the finding is an association, it could partly explain the relationship between lifestyle effects and geographic differences in prostate...
New Consensus-Based Guidance on Managing Cancer Pain in Patients With Opioid Use Disorder or Opioid Misuse
Opioids are a cornerstone of cancer pain management, but there is a lack of consensus on how to treat pain patients with cancer who also have struggled with opioid use disorder or prescription opioid misuse. In a study published by Fitzgerald Jones et al in JAMA Oncology, researchers outlined...
Chiara Cremolini, MD, PhD, Comments on Findings From the PARADIGM Trial
The invited discussant of PARADIGM, Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy, said the findings prospectively confirm the superior benefit of FOLFOX (fluorouracil, leucovorin, oxaliplatin) paired with panitumumab rather than bevacizumab in RAS...
Expert Point of View: Ben Creelan, MD
Ben Creelan, MD, Associate Member of Moffitt Cancer Center, Tampa, Florida, provided some context for the CHRYSALIS study. “This dual bispecific antibody targeting both EGFR and MET clearly has potent single-agent activity in patients with MET exon 14 skipping NSCLC,” he said. “For now, it is not...
Chipping Away at Targetable Mutations in NSCLC: Amivantamab in NSCLC With MET Exon 14 Skipping Mutations
Dual targeting with the bispecific antibody amivantamab-vmjw showed antitumor activity and tolerability in patients with metastatic non–small cell lung cancer (NSCLC) and MET exon 14 skipping mutations, according to results of the ongoing phase I CHRYSALIS study.1,2 Updated results were presented...
Structural Racism and Health-Care System Barriers May Contribute to Breast Biopsy Delays
Black and Asian women are more likely than White women to experience significant delays in getting breast biopsies after a mammogram identifies an abnormality. Moreover, those delays appear to be influenced by screening site–specific factors that may stem from structural racism, according to...
Expert Point of View: Joseph Mikhael, MD, MEd
Invited discussant of the DETERMINATION trial, Joseph Mikhael, MD, MEd, Professor of Applied Cancer Research and Drug Discovery at the Translational Genomics Research Institute, City of Hope Cancer Center, described the many implications of the important findings for DETERMINATION and offered some ...
Early Transplant With Triplet Therapy May Delay Progression of Myeloma, but Individualized Approach Recommended
In the phase III DETERMINATION trial, progression-free survival was significantly improved with triplet induction therapy and early transplantation in newly diagnosed patients with multiple myeloma, but overall survival at 5 years was similar to the nontransplant approach.1 The findings were...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare and...
Raising the Bar: Rethinking the Accelerated Drug Approval Process
Our growing knowledge of the molecular and genomic drivers of cancer has translated into a robust pipeline of promising anticancer agents. However, bringing new drugs from the lab to the patient with cancer can be frustratingly slow. To that end, the accelerated approval system was created by the...
Chemicals in Personal Care Products May Increase Breast Cancer Risk in Black Women
The group of compounds called parabens, which are found in widely used hair and personal care products, may increase breast cancer risk in Black women—more so than in White women—according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. One in eight women in the United...
Study Links Diabetes and Worse Outcomes in Long-Term Survivors of Metastatic Breast Cancer
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a new study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. This is the first study to specifically examine the ...
AI May Be Used to Identify Benign Thyroid Nodules and Reduce Unnecessary Biopsies
Artificial intelligence (AI) may be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. Thyroid nodules are very...
Immunotherapy Has Given Me Back My Life
Hearing the words “You have cancer” is a devastating blow, especially when the biggest health issues you’ve had to contend with over more than 6 decades are common colds and knee and hip replacements. But in 2017, the symptoms I thought were from a lingering summer cold drove me to seek medical...
Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab in Advanced Esophageal Squamous Cell Carcinoma
On May 27, 2022, nivolumab was approved for use in combination with fluoropyrimidine- and platinum-based chemotherapy and in combination with ipilimumab for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.1 Supporting Efficacy Data Approval was based on...
ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...
Ariela L. Marshall, MD, Advocates for Equity and Reproductive Health in the Hematology-Oncology Community
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, FACP, spoke with Ariela L. Marshall, MD, Director, Women’s Hemostasis and Thrombosis Program at Penn Medicine. Along with her clinical and research activities, Dr. Marshall is also an advocate for women’s health and equity in ...
Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors
On June 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval for dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with a BRAF V600E mutation whose disease...
Cancer and War in Ukraine: How the World Can Help Win This Battle
In Ukraine, with a population of about 44 million, there are more than 1.3 million patients with cancer. Approximately 160,000 new cases of cancer are diagnosed each year.1 In almost every region, there are local cancer centers; specialized oncologic centers are located in large cities. In Kyiv,...
Invest in the Unexpected: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
The National Institutes of Health (NIH) now stands as the largest single public funder of biomedical research in the world.1 The FY2022 Consolidated Appropriations Act (H.R. 2471), signed into law in March, increases biomedical research funding by nearly 5%, and it provides a total of $45 billion...
ASCO’s CancerLinQ and Count Me In Collaborate to Empower Patient Participation in Clinical Cancer Research
ASCO’s CancerLinQ® and Count Me In recently announced a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ—a real-world oncology data technology platform developed by...
American Cancer Society Investigators Present Studies on COVID-19 Pandemic, Racial/Ethnic Disparities, and Coverage for Genomic Testing
Investigators at the American Cancer Society presented results of several studies during poster sessions at the 2022 ASCO Annual Meeting. Summaries of a few of these studies are provided here. COVID-19 and Cancer Mortality According to a new study led by researchers at the American Cancer Society,...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
